POCHI: pembrolizumab, CAPOX and bevacizumab in pMMR/MSS colorectal cancer 

David Tougeron, MD, PhD, Poitiers University Hospital, Poitiers, France, discusses findings from the Phase II POCHI trial (NCT04262687) of pembrolizumab with CAPOX and bevacizumab in patients with microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC) and a high immune infiltrate. The investigational therapy resulted in promising response rates and ongoing recruitment is underway. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.